Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...

US pharma giant Pfizer on Saturday announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...

Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the ...

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...

Pfizer Inc.'s (NYSE:PFE) COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and prompting Moderna ...

The FDA approved a new safety warning for Depo-Provera alerting patients to a possible risk for a type of brain tumor called ...

Leading vaccine makers Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) on Wednesday responded to President Donald Trump’s recent criticism that drug companies have yet to justify the success of their ...

Pfizer is penning a cancer discovery pact with Cartography Biosciences that could max out at $865 million biobucks. | Pfizer ...